Next Article in Journal
Advanced Characterization and Sample Preparation Strategies for Nanoformulations
Previous Article in Journal
Paradoxical Roles of Carbon Nanotubes in Cancer Therapy and Carcinogenesis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Opinion

Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going

by
Dmitri Simberg
1,2,* and
S. Moein Moghimi
2,3,4,*
1
Translational Bio-Nanosciences Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
2
Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
3
School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
4
Translational and Clinical Research Institute, Faculty of Health and Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
*
Authors to whom correspondence should be addressed.
J. Nanotheranostics 2024, 5(3), 99-103; https://doi.org/10.3390/jnt5030007
Submission received: 3 July 2024 / Revised: 19 July 2024 / Accepted: 26 July 2024 / Published: 29 July 2024

Abstract

PEGylation technology confers stability and modulates the biological performance of a broad range of preclinical and clinical nanopharmaceuticals. However, the emerging PEG immunogenicity in the general population is thought to impact the efficacy and safety of PEGylated medicines. Despite this, the clinical significance of PEG immunogenicity is still not clear and remains debatable. By considering the strategic importance of the PEGylation technology in nanopharmaceutical engineering, we raise a number of critical questions and briefly discuss gaps in the knowledge of PEG immunogenicity and its clinical significance.
Keywords: antibodies; complement system; immunogenicity; poly(ethylene glycol) antibodies; complement system; immunogenicity; poly(ethylene glycol)

Share and Cite

MDPI and ACS Style

Simberg, D.; Moghimi, S.M. Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going. J. Nanotheranostics 2024, 5, 99-103. https://doi.org/10.3390/jnt5030007

AMA Style

Simberg D, Moghimi SM. Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going. Journal of Nanotheranostics. 2024; 5(3):99-103. https://doi.org/10.3390/jnt5030007

Chicago/Turabian Style

Simberg, Dmitri, and S. Moein Moghimi. 2024. "Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going" Journal of Nanotheranostics 5, no. 3: 99-103. https://doi.org/10.3390/jnt5030007

APA Style

Simberg, D., & Moghimi, S. M. (2024). Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going. Journal of Nanotheranostics, 5(3), 99-103. https://doi.org/10.3390/jnt5030007

Article Metrics

Back to TopTop